Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the six ratings firms that are covering the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $37.33.

Several equities research analysts have recently commented on the stock. Bank of America Corp. cut shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Guggenheim assumed coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price target for the company. Leerink Swann reiterated a “buy” rating on shares of Theravance Biopharma in a research report on Friday, June 10th. Zacks Investment Research cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Finally, Evercore ISI assumed coverage on shares of Theravance Biopharma in a research report on Monday, August 29th. They set a “buy” rating and a $41.00 price target for the company.

In related news, EVP Bradford J. Shafer sold 49,122 shares of Theravance Biopharma stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the transaction, the executive vice president now owns 241,686 shares of the company’s stock, valued at approximately $6,636,697.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brett K. Haumann sold 9,509 shares of Theravance Biopharma stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $27.97, for a total transaction of $265,966.73. Following the transaction, the senior vice president now directly owns 197,391 shares in the company, valued at approximately $5,521,026.27. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bellevue Group AG raised its position in shares of Theravance Biopharma by 1.6% in the second quarter. Bellevue Group AG now owns 11,428 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 180 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Theravance Biopharma by 3.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 25,478 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 815 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp raised its position in shares of Theravance Biopharma by 21.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 13,828 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,419 shares during the last quarter. 69.89% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma (NASDAQ:TBPH) traded down 0.22% on Monday, reaching $36.16. 248,706 shares of the company’s stock traded hands. The firm’s market cap is $1.73 billion. Theravance Biopharma has a 52-week low of $12.10 and a 52-week high of $37.14. The stock’s 50 day moving average is $31.01 and its 200 day moving average is $24.13.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. On average, equities research analysts predict that Theravance Biopharma will post ($4.03) EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPH

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.